Ruxolitinib (Jakafi®)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF): primary MF, post-polycythemia vera MF, and post essential thrombocythemia MF

Patients must meet the following criteria for the indication(s) above:

  • Patients with active serious infections should not be treated until the infection resolves. A complete baseline blood count must be done prior to initiation of therapy and every two-four weeks until the dose is stabilized

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications

Dosing:

Patient dosing based on platelet count

platelet count

100-200 x 109/L

>200 x 109/L

starting dose 15 mg twice daily 20 mg twice daily
  • Dose may be increased in increments of 5 mg twice daily up to a maximum dose of 25 mg twice daily (50 mg per day) Dosing must be adjusted for both renal and hepatic impairment
  • Ruxolitinib should be tapered on discontinuation. The recommendation is to reduce the dose by 5 mg twice daily each week
  • Dose taper is not recommend if discontinuation is due to thrombocytopenia

Approval:

Six months; Treatment should be discontinued at 6 months if no spleen size reduction is seen


 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.